AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

CUPR · NASDAQ · Medical - Instruments & Supplies

Cuprina Class A (CUPR)

Develops prescription live-larva products for chronic-wound debridement.

$2.75

Pre-market−0.09 (−3.17%)

At close$2.84(−2.07%)

Watchlist

In millions of USD, except per-share figures · converted from SGD at the latest rate

In millions	Q4 FY25Dec 2025
Revenue	0
Cost of revenue	0
Gross profit	0
	2
Research & development	0
Selling, general & administrative	2
Operating income	−2
	0
Interest income	0
Interest expense	0
Income before tax	−2
Net income from continuing operations	−2
Net income	−2
EPS, basic	−$0.79
EPS, diluted	−$0.79
Weighted average shares, basic	3
Weighted average shares, diluted	3
EBITDA	−2
Depreciation & amortization	0
EBIT	−2